Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
AstraZeneca and Daiichi Sankyo's Enhertu has been recommended for approval in the EU as a treatment for adult patients with resected HER2-positive breast cancer who have residual disease after neoadjuvant treatment. The CHMP based its opinion on the DESTINY-Breast05 trial, which showed Enhertu reduced the risk of invas
On Monday, AstraZeneca (NASDAQ: AZN ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data and transcripts, visit View the webcast at Summary AstraZeneca reported a 6% growth in total revenue for the fi
Approved In The EU As First Tumor Agnostic Her2 Directed Therapy And Antibody Drug Conjugate For Patients With Previously Treated Her2 Positive Metastatic Solid Tumors